Advertisement

Author: Janine Anthes

SABCS 2020: First Immunotherapy Combo Well-Tolerated

In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...

Read More

SABCS 2020: Update from the DESTINY-Breast01 trial

In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable...

Read More

HBM9036 Nasal Spray for Dry Eye Disease

HBM9036 ophthalmic solution 0.25%,  also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...

Read More

For latest news and updates
Email-id is invalid